Philip Chaikin

Adenosine A _2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

Peter A. LeWitt, Mark Guttman, James W. Tetrud et al. · Annals of Neurology · 2008 · 346 citations

Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Hartmut Derendorf, Lawrence J. Lesko, Philip Chaikin et al. · The Journal of Clinical Pharmacology · 2000 · 204 citations

Translational Medicine, Pharmacokinetic Modeling, Pharmacodynamics +11

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

Mark Stacy, Dee E. Silver, Tilak Mendis et al. · Neurology · 2008 · 181 citations

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study

Emmanuelle Pourcher, Hubert H. Fernandez, Mark Stacy et al. · Parkinsonism & Related Disorders · 2011 · 117 citations

Neurophysiology, Neurological Disorder, Parkinson Disease +9

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Christine E. Swenson, Lois E. Bolcsak, Gerald Batist et al. · Anti-Cancer Drugs · 2003 · 112 citations